Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05740566 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
A Phase 3 study of Small Cell Lung Cancer (SCLC), sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 509
- Enrollment target
- 20
- Study locations
NCT05740566 is a Phase 3 study of Small Cell Lung Cancer (SCLC) that is active but no longer recruiting, run by Amgen. The registered enrollment target is 509 participants, above the 308-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT05740566, a Phase 3 study of Small Cell Lung Cancer (SCLC), is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 509 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Conditions Studied
Interventions
- DRUG Topotecan
- DRUG Lurbinectedin
- DRUG Tarlatamab
- DRUG Amrubicin
Study Locations (20)
New York
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
- Perlmutter Cancer Center at New York University Langone Hospital----Long Island - New York
- Memorial Sloan Kettering Cancer Center - New York
- Northport Veterans Affairs Medical Center - Northport
Illinois
- Northwestern University - Chicago
- University of Illinois Chicago - Chicago
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Alaska
- Alaska Oncology and Hematology - Anchorage
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- University of California Los Angeles - Santa Monica
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2028-03-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05740566
The ClinicalTrials.gov registry entry for NCT05740566 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 308-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (65% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 4 interventions - of which Topotecan is the first listed.
NCT05740566 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT05740566 about?
NCT05740566 is a clinical study titled "Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer". The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
What is the current status of trial NCT05740566?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 509 participants. The study started on 2023-05-31. Estimated completion is 2028-03-26.
What conditions does trial NCT05740566 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC).
What interventions are being tested in trial NCT05740566?
The interventions under investigation include: Topotecan (DRUG), Lurbinectedin (DRUG), Tarlatamab (DRUG), Amrubicin (DRUG).
Who is sponsoring clinical trial NCT05740566?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05740566 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.